Q1 2025 Management View The company announced a strategic restructuring to focus on its LineaRx subsidiary, exiting the DNA Tagging and Security Products and Services segment. This move is expected to ...
Maxim Group analyst Michael Okunewitch maintained a Hold rating on Gilead Sciences (GILD – Research Report) today. The company’s shares closed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback